多尺度技术治疗缺血性心肌病。
Multiscale technologies for treatment of ischemic cardiomyopathy.
机构信息
Center for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
出版信息
Nat Nanotechnol. 2017 Sep 6;12(9):845-855. doi: 10.1038/nnano.2017.167.
Abstract
The adult mammalian heart possesses only limited capacity for innate regeneration and the response to severe injury is dominated by the formation of scar tissue. Current therapy to replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer progressive decay in the heart's pumping capacity to the point of heart failure. Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Here, we outline recent advancements in nanotechnology that could be exploited to overcome the major obstacles in the prevention of and therapy for heart disease. We also discuss emerging trends in nanotechnology affecting the cardiovascular field that may offer new hope for patients suffering massive heart attacks.
摘要
成年哺乳动物的心脏仅具有有限的先天再生能力，严重损伤的反应主要是形成疤痕组织。目前用于替代受损心脏组织的治疗方法仅限于心脏移植，因此许多患者的心脏泵血能力逐渐下降，直至心力衰竭。纳米结构系统有可能彻底改变治疗心血管疾病的预防和治疗方法。在这里，我们概述了纳米技术的最新进展，这些进展可能被利用来克服预防和治疗心脏病的主要障碍。我们还讨论了影响心血管领域的纳米技术的新兴趋势，这些趋势可能为遭受大面积心脏病发作的患者带来新的希望。
相似文献
1
Multiscale technologies for treatment of ischemic cardiomyopathy.多尺度技术治疗缺血性心肌病。
Nat Nanotechnol. 2017 Sep 6;12(9):845-855. doi: 10.1038/nnano.2017.167.
2
Nanomedicine: A great boon for cardiac regenerative medicine.纳米医学：心脏再生医学的一大福音。
Eur J Pharmacol. 2024 Nov 5;982:176969. doi: 10.1016/j.ejphar.2024.176969. Epub 2024 Aug 30.
3
Safety and efficacy of direct cardiac shockwave therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial-an update.直接心脏冲击波治疗缺血性心肌病患者冠状动脉旁路移植术后的安全性和疗效（CAST-HF 试验）：一项随机对照试验的研究方案更新
Trials. 2022 Dec 9;23(1):988. doi: 10.1186/s13063-022-06931-4.
4
Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial.直接心脏冲击波疗法在接受冠状动脉旁路移植术的缺血性心肌病患者中的安全性和有效性（CAST-HF试验）：一项随机对照试验的研究方案
Trials. 2020 May 30;21(1):447. doi: 10.1186/s13063-020-04369-0.
5
Nanomedicine in cardiovascular therapy: recent advancements.纳米医学在心血管治疗中的应用：最新进展
Expert Rev Cardiovasc Ther. 2012 Jun;10(6):805-15. doi: 10.1586/erc.12.41.
6
[Congestive heart failure associated with ischemic cardiopathy].[与缺血性心脏病相关的充血性心力衰竭]
Arq Bras Cardiol. 1995 Apr;64(4):347-54.
7
Nanostructured injectable cell microcarriers for tissue regeneration.用于组织再生的纳米结构可注射细胞微载体
Nanomedicine (Lond). 2016 Jun;11(12):1611-28. doi: 10.2217/nnm-2016-0083. Epub 2016 May 27.
8
Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration.细胞治疗、3D 培养系统和组织工程学在心脏再生中的应用。
Adv Drug Deliv Rev. 2014 Apr;69-70:254-69. doi: 10.1016/j.addr.2013.12.004. Epub 2013 Dec 27.
9
Stem-cell angiogenesis and regeneration of the heart: review of a saga of 2 decades.干细胞与心脏血管生成及再生：20年历程回顾
Clin Cardiol. 2015 May;38(5):309-16. doi: 10.1002/clc.22381. Epub 2015 May 8.
10
Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.欧洲心脏病学会心脏细胞生物学工作组立场文件：缺血性心脏病和心力衰竭心肌修复与再生的细胞疗法
Eur Heart J. 2016 Jun 14;37(23):1789-98. doi: 10.1093/eurheartj/ehw113. Epub 2016 Apr 7.
引用本文的文献
1
Image-Guided Cardiac Regeneration via a 3D Bioprinted Vascular Patch with Built-in CT Visibility.通过具有内置CT可见性的3D生物打印血管补片实现图像引导的心脏再生
Chem Eng J. 2025 Sep 15;520. doi: 10.1016/j.cej.2025.165926. Epub 2025 Jul 12.
2
Mass spectrometry-based top-down proteomics for proteoform profiling of protein coronas.基于质谱的自上而下蛋白质组学用于蛋白质冠层的蛋白质异构体分析。
Nat Protoc. 2025 Aug 5. doi: 10.1038/s41596-025-01229-6.
3
Insights From m6A RNA Methylation: Biomarkers for Diagnosis of Acute Myocardial Infarction.m6A RNA甲基化的见解：急性心肌梗死诊断的生物标志物
J Inflamm Res. 2025 Mar 12;18:3589-3605. doi: 10.2147/JIR.S512476. eCollection 2025.
4
Advances in Conductive Biomaterials for Cardiac Tissue Engineering: Design, Fabrication, and Functional Integration.用于心脏组织工程的导电生物材料进展：设计、制造与功能整合
Polymers (Basel). 2025 Feb 26;17(5):620. doi: 10.3390/polym17050620.
5
Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions.用于心脏再生的胎儿附件来源的同种异体间充质干细胞：基于细胞治疗年龄相关不良状况的未来趋势。
Hum Cell. 2025 Feb 25;38(2):61. doi: 10.1007/s13577-025-01190-2.
6
Nanoparticle-Based Therapies for Cardiovascular Diseases: A Literature Review of Recent Advances and Clinical Potential.基于纳米颗粒的心血管疾病治疗：近期进展与临床潜力的文献综述
Cureus. 2024 Oct 31;16(10):e72808. doi: 10.7759/cureus.72808. eCollection 2024 Oct.
7
Nanomedicine-based strategies for the treatment of vein graft disease.基于纳米医学的静脉移植物疾病治疗策略。
Nat Rev Cardiol. 2025 Apr;22(4):255-272. doi: 10.1038/s41569-024-01094-y. Epub 2024 Nov 5.
8
Microenvironment-responsive nanomedicines: a promising direction for tissue regeneration.环境响应型纳米医学：组织再生的一个有前途的方向。
Mil Med Res. 2024 Oct 21;11(1):69. doi: 10.1186/s40779-024-00573-0.
9
FSTL-1 loaded 3D bioprinted vascular patch regenerates the ischemic heart tissue.负载FSTL-1的3D生物打印血管补片可使缺血性心脏组织再生。
iScience. 2024 Aug 22;27(10):110770. doi: 10.1016/j.isci.2024.110770. eCollection 2024 Oct 18.
10
Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.纳米颗粒作为心血管疾病诊断和治疗的新平台。
Int J Nanomedicine. 2024 Aug 27;19:8831-8846. doi: 10.2147/IJN.S474888. eCollection 2024.
本文引用的文献
1
Personalized protein coronas: a "key" factor at the nanobiointerface.个性化蛋白质冠层：纳米生物界面的“关键”因素。
Biomater Sci. 2014 Sep 29;2(9):1210-1221. doi: 10.1039/c4bm00131a. Epub 2014 May 30.
2
Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics.对聚合物纳米颗粒上体内蛋白质冠形成的机制理解及其对药代动力学的影响。
Nat Commun. 2017 Oct 3;8(1):777. doi: 10.1038/s41467-017-00600-w.
3
Cellular uptake of nanoparticles: journey inside the cell.纳米颗粒的细胞摄取：细胞内之旅
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244. doi: 10.1039/c6cs00636a.
4
Cutting-edge platforms in cardiac tissue engineering.心脏组织工程的前沿平台。
Curr Opin Biotechnol. 2017 Oct;47:23-29. doi: 10.1016/j.copbio.2017.05.008. Epub 2017 Jun 1.
5
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.利用人诱导多能干细胞对酪氨酸激酶抑制剂心脏毒性进行高通量筛选。
Sci Transl Med. 2017 Feb 15;9(377). doi: 10.1126/scitranslmed.aaf2584.
6
Personalized protein corona on nanoparticles and its clinical implications.纳米颗粒上的个性化蛋白质冠层及其临床意义。
Biomater Sci. 2017 Feb 28;5(3):378-387. doi: 10.1039/c6bm00921b.
7
Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.用于疾病建模和药物筛选的人诱导多能干细胞衍生心肌细胞及组织工程策略。
Biotechnol Adv. 2017 Jan-Feb;35(1):77-94. doi: 10.1016/j.biotechadv.2016.12.002. Epub 2016 Dec 20.
8
Cancer nanomedicine: progress, challenges and opportunities.癌症纳米医学：进展、挑战与机遇。
Nat Rev Cancer. 2017 Jan;17(1):20-37. doi: 10.1038/nrc.2016.108. Epub 2016 Nov 11.
9
Nanomedicines for renal disease: current status and future applications.用于肾病的纳米药物：现状和未来应用。
Nat Rev Nephrol. 2016 Dec;12(12):738-753. doi: 10.1038/nrneph.2016.156. Epub 2016 Oct 31.
10
Applications of 3D printing in cardiovascular diseases.3D 打印在心血管疾病中的应用。
Nat Rev Cardiol. 2016 Dec;13(12):701-718. doi: 10.1038/nrcardio.2016.170. Epub 2016 Oct 27.
Zotero 插件